Ethical and legal issues in psychedelic harm reduction and integration therapy
The paper analyses the ethical and legal risks therapists face when supporting clients who use prohibited psychedelics and argues that a harm‑reduction framework enables clinicians to mitigate those risks. It recommends pre‑ and post‑experience sessions and practical strategies so therapists can help clients minimise harms and maximise therapeutic benefit while striving to remain within legal and ethical boundaries.
Abstract
Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed.
Research Summary of 'Ethical and legal issues in psychedelic harm reduction and integration therapy'
Introduction
The paper opens by situating renewed public and scientific interest in psychedelics within a longer cultural and historical context: these substances have been used in spiritual and healing contexts for millennia, enjoyed a period of clinical research in the mid-20th century, were then largely prohibited, and are now experiencing a contemporary resurgence in both clinical trials and public demand. The authors note that several placebo‑controlled, randomised trials and ongoing Phase III studies have produced promising early results for conditions such as PTSD, depression, end‑of‑life distress, addiction, and social anxiety, but legal restrictions mean most psychedelics remain controlled substances. Consequently, many people seeking therapeutic benefit use psychedelics outside regulated settings, creating a need for clinicians to support clients who plan or have had psychedelic experiences. Pilecki and colleagues set out to clarify ethical and legal issues for therapists who wish to provide harm reduction and integration therapy related to psychedelics. The paper aims to describe a harm reduction framework adapted to this context, review relevant background evidence and therapeutic models used in clinical trials, identify the principal risks for clinicians (legal, licensure, malpractice, reputational), and offer practical steps and decision points to mitigate those risks while supporting client safety and benefit. Although focused on a US regulatory context, the authors intend many principles to generalise to other jurisdictions.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typemeta
- Journal
- Topics
- Author
- APA Citation
Pilecki, B., Luoma, J. B., Bathje, G. J., Rhea, J., & Narloch, V. F. (2021). Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduction Journal, 18(1). https://doi.org/10.1186/s12954-021-00489-1
References (13)
Papers cited by this study that are also in Blossom
Luoma, J. B., Chwyl, C., Bathje, G. J. et al. · Journal of Psychoactive Drugs (2020)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
King, C., Nichols, D. E. · Nature Reviews Neuroscience (2013)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Bogenschutz, M. P., Forcehimes, A. A. · Journal of Humanistic Psychology (2016)
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Danforth, A. L., Grob, C. S., Struble, C. et al. · Psychopharmacology (2018)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Schenberg, E. E. · Frontiers in Pharmacology (2018)
Show all 13 referencesShow fewer
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Richards, W. A. · Journal of Humanistic Psychology (2016)
Watts, R., Luoma, J. B. · Journal of Contextual Behavioral Science (2020)
Cited By (15)
Papers in Blossom that reference this study
Avancena, A. L. V., Vuong, L., Kahn, J. G. et al. · Translational Psychiatry (2025)
Fernandes-Nascimento, M. H., Negrão, A. B., Viana-Ferreira, K. et al. · Journal of Psychoactive Drugs (2023)
Jacobs, E., Murphy-Beiner, A., Rouiller, I. et al. · Neuroethics (2023)
Greń, J., Tylš, F., Lasocik, M. et al. · Frontiers in Psychology (2023)
Bremler, R., Katati, N., Shergill, P. et al. · Scientific Reports (2023)
Dougherty, R. F., Clarke, P., Kuc, J. et al. · Psychopharmacology (2023)
Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2023)
Lutkajtis, A., Evans, J. · Journal of Psychedelic Studies (2023)
Devenot, N., Seale-Feldman, A., Smith, E. et al. · Kennedy Institute of Ethics Journal (2022)
Glynos, N., Fields, C. W., Barron, J. et al. · Journal of Psychoactive Drugs (2022)
Show all 15 papersShow fewer
Hipólito, I., Mago, J., Rosas, F. E. et al. · Psyarxiv (2022)
Johnson, S., Letheby, C. · Journal of Psychedelic Studies (2022)
Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)
Earleywine, M., Low, F., Lau, C. et al. · Journal of Humanistic Psychology (2022)
Williams, M. L., Korevaar, D., Harvey, R. et al. · Frontiers in Psychiatry (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.